(Q43219612)

16 November 2017

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine (English)

1 reference

16 November 2017

visceral leishmaniasis

1 reference

1 reference

1

1 reference

16 November 2017

André de Figueiredo Barbosa

2

1 reference

16 November 2017

Fernanda Nunes Santos

3

1 reference

16 November 2017

Gulnara Patrícia Borja-Cabrera

4

1 reference

16 November 2017

Dirlei Nico

5

1 reference

16 November 2017

Lucieri Olegário Pereira Souza

6

1 reference

16 November 2017

Carolina de Oliveira Mendes-Aguiar

7

1 reference

16 November 2017

Edilma Paraguai de Souza

8

1 reference

16 November 2017

Patrícia Fampa

9

1 reference

16 November 2017

Luciana Ellner Parra

10

1 reference

16 November 2017

Ingrid Menz

11

1 reference

16 November 2017

Jaime Galvão Dias

12

1 reference

16 November 2017

Sandra Maria de Oliveira

13

1 reference

16 November 2017

Clarisa Beatriz Palatnik-de-Sousa

14

1 reference

16 November 2017

language of work or name

English

0 references

publication date

15 December 2005

1 reference

16 November 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

16 November 2017

24

1 reference

16 November 2017

13

1 reference

16 November 2017

2423-2431

1 reference

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

16 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Vaccines for parasitic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Plasmodium vivax malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Parasitic adaptive mechanisms in infection by leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Evidence that the vectorial competence of phlebotomine sand flies for different species of Leishmania is controlled by structural polymorphisms in the surface lipophosphoglycan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Stage-specific binding of Leishmania donovani to the sand fly vector midgut is regulated by conformational changes in the abundant surface lipophosphoglycan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Leishmania chagasi: lipophosphoglycan characterization and binding to the midgut of the sand fly vector Lutzomyia longipalpis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Resolution of rabbit polyclonal anti-fluorescein Fab (IgG) fragments into subpopulations differing in affinity and spectral properties of bound ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Intracellular Leishmania amazonensis killing induced by the guanine nucleoside 8-bromoguanosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The role of phosphoglycans in Leishmania-sand fly interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

A role for insect galectins in parasite survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The developmental biology of Leishmania promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The effect of immune sera from hamsters immunized with sandfly gut and whole body extract antigens on the fecundity and mortality of Phlebotomus duboscqi (Diptera: Psychodidae).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Transmission blocking vaccine studies in leishmaniasis: I. Lipophosphoglycan is a promising transmission blocking vaccine molecule against cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

The effect of post-bloodmeal nutrition of Phlebotomus papatasi on the transmission of Leishmania major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Ecological interactions of visceral leishmaniasis in the state of Bahia, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Leishmanial infections in Lutzomyia longipalpis and Lu. antunesi (Diptera: Psychodidae) on the island of Marajó, Pará State, Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

Leishmaniasis in Brazil. XXI. Visceral leishmaniasis in the Amazon Region and further observations on the role of Lutzomyia longipalpis (Lutz & Neiva, 1912) as the vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.061

10.1016/J.VACCINE.2005.11.061

7 January 2021

Identifiers

DOI

1 reference

16 November 2017

1 reference